Skip to content

Geron GERN Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
Exelixis logo
ExelixisEXEL
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's proceeds from exercises of stock options and other stock issuances?
Geron (GERN) reported proceeds from exercises of stock options and other stock issuances of $914K in Q1 2026.
How has Geron's proceeds from exercises of stock options and other stock issuances changed year-over-year?
Geron's proceeds from exercises of stock options and other stock issuances increased by 257.0% year-over-year, from $256K to $914K.
What is the long-term trend for Geron's proceeds from exercises of stock options and other stock issuances?
Over 3 years (2021 to 2025), Geron's proceeds from exercises of stock options and other stock issuances has grown at a 41.7% compound annual growth rate (CAGR), from $797K to $2.27M.